Want to see KALA full AI Analyst Report?
KALA Stock Chart & Stats
$0.62
-$0.34(-4.42%)
At close: 4:00 PM EST
$0.62
-$0.34(-4.42%)
Day’s Range― - ―
52-Week Range$0.73 - $1,030.00
Previous CloseN/A
Volume15.45K
Average Volume (3M)1.94M
Market Cap
$14.42M
Enterprise Value$94.00
Total Cash (Recent Filing)$8.76M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta1.84
Next Earnings
Aug 06, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.90
Shares Outstanding18,589,832
10 Day Avg. Volume624,022
30 Day Avg. Volume1,940,241
Financial Highlights & Ratios
PEG Ratio0.16
Price to Book (P/B)32.38
Price to Sales (P/S)0.00
P/FCF Ratio-7.08
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-26.5
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Improved Leverage / No DebtElimination of debt materially reduces financial risk and interest obligations, improving balance-sheet resilience. For a pre-revenue biotech this lowers near-term insolvency risk and preserves optionality for raising non-debt capital or funding R&D without onerous fixed charges.
Clinical-stage Antibody-focused PipelineA focused antibody platform targeting autoimmune and inflammatory pathways aligns with enduring therapeutic demand and validated modality economics. Clinical-stage programs provide structural value drivers (data/regulatory readouts) that can create durable value if trials advance successfully.
Positive And Rising Equity BufferAn improving equity position offers a capital buffer against losses and reduces immediate insolvency risk. For a cash-burning clinical biotech, higher equity supports continued R&D spend and gives management more runway flexibility when negotiating financing or partnerships.
Bears Say
Zero Revenue BaseHaving no revenue eliminates any gross-profit foundation and means the company cannot internally fund development or operating expenses. Over the medium term this forces reliance on external financing or partnerships, increasing dilution and execution dependency.
Sustained And Accelerating Cash BurnPersistent negative operating and free cash flow, with a notable TTM decline, creates a structural funding requirement. This accelerates the need for dilutive financing or non-dilutive partnerships and constrains the firm's ability to sustain multi-year clinical programs without external support.
Smaller Balance Sheet And Limited Operating ScaleA reduced asset base and small organizational scale limit capacity to run parallel trials, absorb setbacks, or internalize complex development tasks. This elevates operational and execution risk and increases dependency on CROs, partners, or additional funding to scale programs.
KALA BIO News
KALA FAQ
What was KALA BIO’s price range in the past 12 months?
KALA BIO lowest stock price was $0.73 and its highest was $1030.00 in the past 12 months.
What is KALA BIO’s market cap?
KALA BIO’s market cap is $14.42M.
When is KALA BIO’s upcoming earnings report date?
KALA BIO’s upcoming earnings report date is Aug 06, 2026 which is in 16 days.
How were KALA BIO’s earnings last quarter?
KALA BIO released its earnings results on May 19, 2026. The company reported -$0.136 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.
Is KALA BIO overvalued?
According to Wall Street analysts KALA BIO’s price is currently Overvalued.
Does KALA BIO pay dividends?
KALA BIO does not currently pay dividends.
What is KALA BIO’s EPS estimate?
KALA BIO’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does KALA BIO have?
KALA BIO has 18,589,832 shares outstanding.
What happened to KALA BIO’s price movement after its last earnings report?
KALA BIO reported an EPS of -$0.136 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -6.642%.
Which hedge fund is a major shareholder of KALA BIO?
Currently, no hedge funds are holding shares in KALA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
KALA BIO
Kala Bio, Inc. functions as a biopharmaceutical company dedicated to the creation and commercialization of new therapeutic solutions. The core of their strategy involves utilizing proprietary nanoparticle technology, specifically mucus penetrating particles (MPPs). Initially, their focus for these treatments is directed towards ophthalmic diseases. The company was established in 2009 by co-founders Justin Hanes, Robert S. Langer, and Colin R. Gardner, and its headquarters are located in Arlington, Massachusetts.
Technical Analysis
Ownership Overview
3.61% Insiders
0.36% Mutual Funds
― Other Institutional Investors
94.85% Public Companies and
Individual Investors